EGFR and non-small cell lung carcinoma: Additionally, it was shown that the patients who harbor EGFR/RB1/TP53 mutations at baseline, who represent 5% of patients with EGFR-mutant NSCLC, represent a distinct subgroup of patients at high risk of histologic transformation but also with poorer outcome irrespective of the transformation itself [77].